An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study-Reference-Cited by-同舟云学术

An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study

Published:2022-08-04 Issue:5 Volume:140 Page:516-520
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Li Si-Qi¹,Xu Lan-Ping¹,Wang Yu¹,Zhang Xiao-Hui¹^ORCID,Chen Huan¹,Chen Yu-Hong¹,Wang Feng-Rong¹,Han Wei¹,Sun Yu-Qian¹,Yan Chen-Hua¹,Lv Meng¹,Tang Fei-Fei¹,Mo Xiao-Dong¹,Liu Yan-Rong¹,Liu Kai-Yan¹,Chang Ying-Jun¹^ORCID,Huang Xiao-Jun¹²³^ORCID

Affiliation:

1. 1Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Peking University People’s Hospital & Peking University Institute of Hematology, Beijing, China;

2. 2Peking-Tsinghua Center for Life Sciences, Beijing, China; and

3. 3Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, China

Abstract

Li et al delineate a novel technique for assessing measurable residual disease (MRD) by the assessment of isolated leukemia stem cells (LSCs). They report that assessment of MRD in LSCs provides a better prediction of outcome than standard multiparameter flow cytometry.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

https://ashpublications.org/blood/article-pdf/140/5/516/1912184/bloodbld2021014604.pdf

Reference25 articles.

1. 2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party;Heuser;Blood.,2021

2. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis;Chang;J Hematol Oncol.,2017

3. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia;Fenwarth;Blood.,2021

4. Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation;Guo;Cell Mol Immunol.,2021

5. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia;Freeman;J Clin Oncol.,2013

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of the primitive marker CD133 in CD34‐negative acute myeloid leukemia for the detection of leukemia stem cells;Cytometry Part B: Clinical Cytometry;2024-08-23

2. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?;Blood Reviews;2024-08

3. Profile of Dr. Xiao-Jun Huang;Science China Life Sciences;2024-07-29

4. Immunophenotypic features of early haematopoietic and leukaemia stem cells;International Journal of Laboratory Hematology;2024-07-24

5. Pretransplantation risk factors for MRD after allogeneic stem cell transplantation in AML patients: A prospective study;2024-06-07